SIRT6 and prostate carcinoma: Knockdown of SIRT6 in prostate cancer cells results in cell cycle arrest at sub-G1 phase, increased apoptosis, increased DNA damage, and decreased BCL2 expression, thereby reducing cancer cell viability and enhancing chemotherapeutic sensitivity (122).